Nasdaq:US$11.89 (+1.18) | HKEX:HK$17.64 (+0.76) | AIM:£2.10 (+0.3)
主要股东

和黄医药共发行864,775,340股普通股。于纳斯达克上市的每股美国存托股份(ADS) 相当于五股普通股。

仅作说明:如果转换所有普通股, 则相当于172,955,068股纳斯达克交易的ADS。

就和黄医药而言,其已发行股本中约40.62%并非由公众持有,而是由和黄医药的董事、高级行政人员及长江和记实业有限公司持有。长江和记实业有限公司为和黄医药主要股东。

和黄医药股本中之主要和重大权益的披露受 (i) 英国金融行为监管局(U.K. Financial Conduct Authority)披露指引及透明度规则(Disclosure Rules and Transparency Rules)第 5 章条文规定(已被纳入本公司的组织章程细则);(ii) 美国 1934 年证券交易法的约束;以及 (iii) 香港证券及期货条例(香港法律第571 章)。

就和黄医药所知,持有和黄医药已发行股本之 3% 或以上的股东及其董事(截至上次更新)的权益载于下表。

最后更新时间:2022年 9月7日

主要股东

股东 持有股份╱拥有权益之股份数目 所占已发行股本的概约百分比
CK Hutchison Holdings Limited (1) 332,574,650 38.47%
The Capital Group Companies, Inc. (2) 78,467,580 9.08%
M&G Plc (3) 50,354,476 5.82%
The Goldman Sachs Group, Inc.(4) 44,631,711 5.16%
CA Fern Parent (5)(6) 40,847,500 4.72%
Canada Pension Plan Investment Board (6)(7) 26,883,270 3.11%
Notes:
The above table sets out the interests of certain shareholders, insofar as HUTCHMED is aware based on public disclosure as of May 31, 2022. Includes the interests and short positions in the shares or underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under Section 336 of the SFO, or as otherwise notified to the Company and HKEX under Part XV of the SFO. For details of the capacity of each substantial shareholder’s interests, please refer to the “Interests and Short Positions of Shareholders Discloseable under the Securities and Futures Ordinance” section in the 2022 Interim Report. The above table includes Long Positions only – excludes short positions and lending pools.
(1) Please refer to 2022 Interim Report for details. As of July 15, 2021, notified via disclosure form 2 filed with the Hong Kong Stock Exchange on July 19, 2021.
(2) As of June 10, 2022, notified via disclosure form 2 filed with the Hong Kong Stock Exchange on June 13, 2022.
(3) As of June 16, 2022, notified via disclosure form 2 filed with the Hong Kong Stock Exchange on June 17, 2022.  Held through indirect wholly-owned subsidiary M&G Investment Management Limited.  As notified on July 29, 2019, prior to the demerger of M&G plc from Prudential plc on October 21, 2019.
(4) As of June 29, 2022, notified via disclosure form 2 filed with the Hong Kong Stock Exchange on July 5, 2022.
(5) CA Fern Parent is wholly owned by several entities which are, by and through their control affiliates (including their respective general partners), ultimately controlled (directly or indirectly) by The Carlyle Group Inc., but The Carlyle Group Inc. has no beneficial interest in the underlying securities of the Company. As of Jun 30, 2021, notified via disclosure form TR-1 filed on AIM on July 2, 2021.
(6) Includes Shares subscribed for as a Cornerstone Investor in the Company’s Global Offering in June 2021.
(7) As of June 30, 2021, notified via disclosure form TR-1 filed on AIM on July 16, 2020.

董事

董事 持有股份╱
相关股份数目
所占已发行股本的概约百分比
苏慰国 8,162,525 0.94%
郑泽锋 3,933,925 0.46%
杜志强 2,466,185 0.29%
施熙德 1,200,000 0.14%
Dan ELDAR 150,660 0.02%
莫树锦 136,705 0.02%
Karen FERRANTE 109,805 0.01%
Paul CARTER 108,925 0.01%
Graeme JACK 101,695 0.01%
孙乐非 0 0%
Notes:
As of June 30, 2022.
Includes the interests and short positions of the Directors and chief executive of the Company in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “SFO”)) which were notified to the Company and The Stock Exchange of Hong Kong Limited (the “HKEX”) pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which the Directors and chief executive of the Company were deemed or taken to have under such provisions of the SFO), or which were recorded in the register required to be kept by the Company pursuant to Section 352 of the SFO, or as otherwise notified to the Company and the HKEX pursuant to the Code on Dealings in Shares by Directors adopted by the Company. For details of the capacity and nature of each Director’s interests, please refer to the “Information on Directors” section in the 2021 Annual Report.